Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels

Acta Oncologica

Volumn 50, Issue 3, 2011, Pages 338-343

  Iiristo, Mariann ^a   Wiklund, Tom ^b   Wilking, Nils ^a   Bergh, Jonas ^a   Brandberg, Yvonne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; COGNITION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; EMOTIONAL STABILITY; FATIGUE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PHYSICAL CAPACITY; POSTAL MAIL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SOCIAL BEHAVIOR; SOCIAL INTERACTION; STOMACH PAIN; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INDIVIDUALITY; INDIVIDUALIZED MEDICINE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REFERENCE VALUES; RESEARCH DESIGN;

EID: 79952677641     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.557089     Document Type: Article

References (24)

1. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstr öm P, et al. Tailored FEC compared with marrowsupported high-dose chemotherapy as adjuvant treatment of high-risk breast cancer patients: Results from a randomised study. Lancet 2000;356:1384-91.
2. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstr öm P, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007; 18:694-700. (Pubitemid 46523273)
3. Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, et al. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow supported high-dose chemotherapy with cyclophosphamide thiotepa, and carboplatin or tailored therapy with flourouracil, epirubicin, and cyclophophamide: Scandinavian Breast Group Study 9401. J Clin Oncol 2003;21:3659-64. (Pubitemid 46594060)
4. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. Natl Cancer Inst 2002;94:1883-8. (Pubitemid 36104633)
5. Sandström M, Freijs A, Larsson R, Nygren P, Fjällskog ML, Bergh J, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581-8.
6. Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J 2007;13:581-7. (Pubitemid 350045708)
7. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. (Pubitemid 23073154)
8. Bergman B, Sullivan M, Sör enson S. Quality of life during chemotherapy for small cell lung cancer. I. An evaluation with generic health measures. Acta Oncol 1991;30:947-57.
9. Sigurdardottir V, Brandberg Y, Sullivan M. Criterion-based validation of the EORTC QLQ C-36 in advanced melanoma: The CIPS questionnaire and proxy raters. Qual Life Res 1996;5:375-86. (Pubitemid 26228470)
10. Fayers PM, Aaronson NK, Bjordal K, Grønvold M, Curran D, Bottomley A. EORTC QLQ-C30: Scoring Manual. Brussels, Belgium: European Organization for Research and Treatment of Cancer Quality of Life Study Group; 2002.
11. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89;1837-42. (Pubitemid 37533256)
12. Colleoni M, Price K, Castiglione-Gertsch M, Coates A, Lindtner J, Collins J, et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 1998;34:1693-700. (Pubitemid 28474221)
13. Paridaens R, Wildiers J, Dumez H. Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): A retrospective analysis. In: Rowett L, editor. Annals of Oncology. 27th ESMO Congress 2002, 18-22 October. Abstract 161. Nice: Oxford University Press; 2002. p 45.
14. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763-6. (Pubitemid 29389629)
15. Saarto T, Blomqvist C, Rissanden P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301-5. (Pubitemid 27019578)
16. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246-57. (Pubitemid 32552809)
17. Szutowicz E, Radecka B, Dziadziuszko R. Peripheral blood count nadirs during adjuvant CMF chemotherapy for breast cancer-lack of prognostic relevance: 3rd European Beast Cancer Conference, Barcelona. Abstract 205. Eur J Cancer 2002;38(Suppl 3):S93.
18. Bergh, J. Quo Vadis with targeted drugs. J Clin Oncol 2009; 27:2-5.
19. Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, et al. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol 2007;25:5403-9. (Pubitemid 350232216)
20. Luoma ML, Hakamies-Blomqvist L, Sjös tröm J, Mouridsen H, Pluzanska A, Malmstr öm P, et al. Physical performance, toxicity, and quality of life as assessed by the physician and the patient. Acta Oncol 2002;41:44-9. (Pubitemid 34293358)
21. Genre D, Protiére C, Macquart-Moulin G, Gravis G, Camerlo J, Alzieu C, et al. Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: Impact of length of cycles. Supp Care Cancer 2002;10:222-30. (Pubitemid 36056296)
22. Hurria A, Somio G, Ahles T. Renaming "Chemobrain" . Cancer Invest 2007;25:373-7.
23. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 2003;95:190-7. (Pubitemid 36240631)
24. Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQC30. Eur J Cancer 2002;38: S125-33. (Pubitemid 34169774)